Rallybio Corp - Asset Resilience Ratio
Rallybio Corp (RLYB) has an Asset Resilience Ratio of 37.52% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Rallybio Corp total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Rallybio Corp's Asset Resilience Ratio has changed over time. See RLYB net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Rallybio Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Rallybio Corp worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $23.36 Million | 37.52% |
| Total Liquid Assets | $23.36 Million | 37.52% |
Asset Resilience Insights
- Very High Liquidity: Rallybio Corp maintains exceptional liquid asset reserves at 37.52% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Rallybio Corp Industry Peers by Asset Resilience Ratio
Compare Rallybio Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Rallybio Corp (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Rallybio Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 37.52% | $23.36 Million | $62.26 Million | -38.25pp |
| 2024-12-31 | 75.77% | $51.61 Million | $68.11 Million | +1.88pp |
| 2023-12-31 | 73.89% | $85.44 Million | $115.62 Million | +11.80pp |
| 2022-12-31 | 62.09% | $112.04 Million | $180.44 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $182.19 Million | -- |
About Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical … Read more